Tumor Infiltrating Lymphocytes (TIL) Recognize Unique Somatic Mutations and Mediate Objective Clinical Responses in Metastatic Breast Cancer

The purpose of this study is to investigate the immunogenicity of tumor mutations in patients with metastatic cancer. Harvest and analysis of progressing metastatic lesions are used for generation of tumor infiltrating lymphocyte (TIL) cultures and the detections of somatic mutations. In vitro T cell activation assays are used to examine the immune recognition of tumor mutations by autologous TIL.
Once a candidate is determined to have a cell product that meets the requirements of one of the Surgery Branch clinical trials, the candidate is evaluated for enrollment in a prospective adoptive cell therapy trial.]]>
Patients must be/have:

Age ≥ 18 years and ≤ 70 years
Metastatic breast cancer refractory to standard chemotherapy
Normal basic laboratory values

Patients may not have:

Concurrent major medical illnesses
Severe hepatic function impairment due to liver metastatic burden
Unpalliated biliary or bowel occlusion, cholangitis, or digestive tract bleeding
Any form of immunodeficiency
Severe hypersensitivity to any of the agents used in this study

]]>